Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811925 | 0.90 | CACNA1G (0.42) | P2RX7CACNA1GCACNA1HCACNA1ITP53 | |
| SCHEMBL538580 | 0.89 | CACNA1G (0.41) | P2RX7CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL2815942 | 0.87 | MC4R (0.43) | P2RX7POLBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL2812033 | 0.86 | P2RX7 (0.42) | P2RX7CACNA1GCACNA1HCACNA1IKMT2A | |
| SCHEMBL2814282 | 0.85 | KMT2A (0.42) | P2RX7CACNA1GCACNA1HCACNA1IGAA | |
| SCHEMBL2812141 | 0.85 | ALDH1A1 (0.43) | POLBCACNA1GCACNA1HCACNA1IGAA | |
| SCHEMBL538332 | 0.84 | CACNA1G (0.39) | CACNA1GCACNA1HCACNA1IGAALMNA | |
| SCHEMBL537587 | 0.84 | ALDH1A1 (0.48) | POLBTP53LMNAKMT2A | |
| SCHEMBL2811162 | 0.83 | USP2 (0.39) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL538002 | 0.83 | KDM1A (0.41) | CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | P2RX7 103/4885POLB 345/4885CACNA1G 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.